跳到主要內容區
 
:::

[新聞] : 清冠研發成果發表文章和得獎一覽表

  • 清冠中藥 : 「臺灣清冠一號(NRICM101)和臺灣清冠二號(NRICM102)」研發成果刊登於高點數國際學術期刊(SCI): 
  1. Tsai KCHuang YC, Liaw CC, Tsai CI, Chiou CT, Lin CJ, Wei WC, Lin SJ, Tseng YH, Yeh KM, Lin YL, Jan JT, Liang JJ, Liao CC, Chiou WF, Kuo YH, Lee SM, Lee MY, Su YC. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother. (2021) Jan;133:111037. doi: 10.1016/j.biopha.2020.111037. https://doi.org/10.1016/j.biopha.2020.111037
  2. Wei WC, Liaw CC, Tsai KC, Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC*, and Su YC*. Targeting spike protein-induced TLR/NET axis by Covid-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res. (2022) Sep 2:106424. doi: 10.1016/j.phrs.2022.106424. https://doi.org/10.1016/j.phrs.2022.106424
  3. Tseng YH, Lin SJ, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol Res. (2022) Aug 23;184:106412. doi: 10.1016/j.phrs.2022.106412. https://doi.org/10.1016/j.phrs.2022.106412
  4. Su YC, Huang GJ, Lin JG. Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101) (2022). Front Pharmacol . 2022 Oct 5:13:928106. doi: 10.3389/fphar.2022.928106. eCollection 2022. https://doi.org/10.3389/fphar.2022.928106
  5. Wei WC, Tsai KC, Liaw CC, Chiou CT, Tseng YH, Liao GY, Lin YC, Chiou WF, Liou KT, Yu IS, Shen YC*, Su YC*. NRICM101 ameliorates SARS-CoV-2–S1-induced pulmonary injury in K18-hACE2 mice model. (2023) Front. Pharmacol. Volume 14 - 2023 | doi: 10.3389/fphar.2023.1125414. https://www.frontiersin.org/articles/10.3389/fphar.2023.1125414/full
  6. Lin JG, Huang GJ, Su YC.  Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19. (2023) J Biomed Sci. 2023 May 3;30(1):30. doi: 10.1186/s12929-023-00923-5. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00923-5
  7. Ho ST, Tsai YN, Su YC. The development and application of NRICM101 and NRICM102 for the treatment of COVID-19. (2023) J Formos Med Assoc. 2023 Jul;122(7):525-527. doi: 10.1016/j.jfma.2023.04.015. Epub 2023 Apr 26. https://www.sciencedirect.com/science/article/pii/S0929664623001419
  8. Chang CC, Wang YH, Yen JC, Liaw CC, Tsai KC, Wei WC, Chiou WF, Chiou CT, Liou KT, Shen YC*, Su YC*. NRICM101 in combatting COVID-19 induced brain fog: Neuroprotective effects and neurovascular integrity preservation in hACE2 mice. (2024) Journal of Traditional and Complementary Medicine. (2024)  https://www.sciencedirect.com/science/article/pii/S2225411024000841

 

  • 「臺灣清冠一號(NRICM101)」研發成果已獲頒四個重要生技類獎項:
  1. 1. 於台北生技展獲頒技轉合作獎「金獎」和獎金80萬:111812日,以「臺灣清冠中藥用於治療新冠肺炎及其併發症之研發」,於2022年臺北生技獎頒獎典禮上,獲得技轉合作類的最高榮譽,並由柯文哲市長親頒台北生技獎-金獎」獎座。
  2. 2. 獲頒「藥物科技研究發展-銀牌」:110年11月30日參加「2021藥物科技研究發展」競賽,在以西藥為主流的藥品類競賽中,「臺灣清冠一號」獲頒「藥品類銀質獎」。
  3. 3. 獲科技部頒發「未來科技獎」:110年10月16日參加「2021臺灣創新技術博覽會-未來科技館」競賽獲獎。
  4. 4. 獲頒「2021國家新創獎」:獲獎日期110年12月23日。

 

 

瀏覽數: